Global Breakthrough Therapy Market
Global Breakthrough Therapy Market

Breakthrough Therapy Comprehensive Study by Application (Oncology, Infectious Diseases, Rare Diseases, Autoimmune Diseases, Pulmonary Diseases, Neurological Disorders, Others), End-users (Hospitals, Clinics, Ambulatory Services), Drug Class (Oncology, Anti-Viral, Neurology, Others) Players and Region - Global Market Outlook to 2025

Breakthrough Therapy Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Dec 2020 Edition 219 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Breakthrough Therapy Market?

A breakthrough therapy designation is for a drug that treats a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies. The factors such as the Increased Number of Cancer Therapies and the Increasing Number of Molecules Getting BT Status are driving the global breakthrough therapy market.

The market study is being classified, by Application (Oncology, Infectious Diseases, Rare Diseases, Autoimmune Diseases, Pulmonary Diseases, Neurological Disorders and Others) and major geographies with country level break-up.

C.H. Boehringer Sohn AG & Ko. KG (Germany), Acadia Pharmaceuticals, Inc. (United States), GlaxoSmithKline plc. (United Kingdom), AstraZeneca plc (United Kingdom), Merck & Co., Inc. (United States), Pfizer Inc. (United States), AbbVie Inc (United States), Bristol-Myers Squibb Company (United States), Genentech Inc (United States) and Gilead Sciences, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Novartis International AG (Switzerland) and Vertex Pharmaceuticals Incorporated (United States).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Breakthrough Therapy market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Breakthrough Therapy market by Type, Application and Region.

On the basis of geography, the market of Breakthrough Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Number of Cancer Therapies
  • Increasing Number of Molecules Getting BT Status

Market Trend
  • Rise in the Healthcare Spending

Restraints
  • High Cost of Breakthrough Therapy

Opportunities
  • Increasing Prevalence of Cancer Disease
  • Growth in the Healthcare Industry

Challenges
  • Stringent Government Rules and Regulations





Key Target Audience
Breakthrough Therapy Providers, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Oncology
  • Infectious Diseases
  • Rare Diseases
  • Autoimmune Diseases
  • Pulmonary Diseases
  • Neurological Disorders
  • Others
By End-users
  • Hospitals
  • Clinics
  • Ambulatory Services

By Drug Class
  • Oncology
  • Anti-Viral
  • Neurology
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Number of Cancer Therapies
      • 3.2.2. Increasing Number of Molecules Getting BT Status
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Rise in the Healthcare Spending
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
  • 5. Global Breakthrough Therapy, by Application, End-users, Drug Class and Region (value) (2014-2019)
    • 5.1. Introduction
  • 6. Breakthrough Therapy: Manufacturers/Players Analysis
    • 6.1. Company Profile
      • 6.1.1. C.H. Boehringer Sohn AG & Ko. KG (Germany)
        • 6.1.1.1. Business Overview
        • 6.1.1.2. Products/Services Offerings
        • 6.1.1.3. Financial Analysis
        • 6.1.1.4. SWOT Analysis
      • 6.1.2. Acadia Pharmaceuticals, Inc. (United States)
        • 6.1.2.1. Business Overview
        • 6.1.2.2. Products/Services Offerings
        • 6.1.2.3. Financial Analysis
        • 6.1.2.4. SWOT Analysis
      • 6.1.3. GlaxoSmithKline plc. (United Kingdom)
        • 6.1.3.1. Business Overview
        • 6.1.3.2. Products/Services Offerings
        • 6.1.3.3. Financial Analysis
        • 6.1.3.4. SWOT Analysis
      • 6.1.4. AstraZeneca plc (United Kingdom)
        • 6.1.4.1. Business Overview
        • 6.1.4.2. Products/Services Offerings
        • 6.1.4.3. Financial Analysis
        • 6.1.4.4. SWOT Analysis
      • 6.1.5. Merck & Co., Inc. (United States)
        • 6.1.5.1. Business Overview
        • 6.1.5.2. Products/Services Offerings
        • 6.1.5.3. Financial Analysis
        • 6.1.5.4. SWOT Analysis
      • 6.1.6. Pfizer Inc. (United States)
        • 6.1.6.1. Business Overview
        • 6.1.6.2. Products/Services Offerings
        • 6.1.6.3. Financial Analysis
        • 6.1.6.4. SWOT Analysis
      • 6.1.7. AbbVie Inc (United States)
        • 6.1.7.1. Business Overview
        • 6.1.7.2. Products/Services Offerings
        • 6.1.7.3. Financial Analysis
        • 6.1.7.4. SWOT Analysis
      • 6.1.8. Bristol-Myers Squibb Company (United States)
        • 6.1.8.1. Business Overview
        • 6.1.8.2. Products/Services Offerings
        • 6.1.8.3. Financial Analysis
        • 6.1.8.4. SWOT Analysis
      • 6.1.9. Genentech Inc (United States)
        • 6.1.9.1. Business Overview
        • 6.1.9.2. Products/Services Offerings
        • 6.1.9.3. Financial Analysis
        • 6.1.9.4. SWOT Analysis
      • 6.1.10. Gilead Sciences, Inc. (United States)
        • 6.1.10.1. Business Overview
        • 6.1.10.2. Products/Services Offerings
        • 6.1.10.3. Financial Analysis
        • 6.1.10.4. SWOT Analysis
  • 7. Global Breakthrough Therapy Sale, by Application, End-users, Drug Class and Region (value) (2020-2025)
    • 7.1. Introduction
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Company Basic Information, Sales Area and Its Competitors
  • Table 2. Company Basic Information, Sales Area and Its Competitors
  • Table 3. Company Basic Information, Sales Area and Its Competitors
  • Table 4. Company Basic Information, Sales Area and Its Competitors
  • Table 5. Company Basic Information, Sales Area and Its Competitors
  • Table 6. Company Basic Information, Sales Area and Its Competitors
  • Table 7. Company Basic Information, Sales Area and Its Competitors
  • Table 8. Company Basic Information, Sales Area and Its Competitors
  • Table 9. Company Basic Information, Sales Area and Its Competitors
  • Table 10. Company Basic Information, Sales Area and Its Competitors
  • Table 11. Research Programs/Design for This Report
  • Table 12. Key Data Information from Secondary Sources
  • Table 13. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 5. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue: by Geography 2019
  • Figure 6. Acadia Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 7. Acadia Pharmaceuticals, Inc. (United States) Revenue: by Geography 2019
  • Figure 8. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 9. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2019
  • Figure 10. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 11. AstraZeneca plc (United Kingdom) Revenue: by Geography 2019
  • Figure 12. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 13. Merck & Co., Inc. (United States) Revenue: by Geography 2019
  • Figure 14. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 15. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 16. AbbVie Inc (United States) Revenue, Net Income and Gross profit
  • Figure 17. AbbVie Inc (United States) Revenue: by Geography 2019
  • Figure 18. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2019
  • Figure 20. Genentech Inc (United States) Revenue, Net Income and Gross profit
  • Figure 21. Genentech Inc (United States) Revenue: by Geography 2019
  • Figure 22. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Gilead Sciences, Inc. (United States) Revenue: by Geography 2019
Some of the key companies/manufacturers profiled in the report
  • C.H. Boehringer Sohn AG & Ko. KG (Germany)
  • Acadia Pharmaceuticals, Inc. (United States)
  • GlaxoSmithKline plc. (United Kingdom)
  • AstraZeneca plc (United Kingdom)
  • Merck & Co., Inc. (United States)
  • Pfizer Inc. (United States)
  • AbbVie Inc (United States)
  • Bristol-Myers Squibb Company (United States)
  • Genentech Inc (United States)
  • Gilead Sciences, Inc. (United States)
Additional players considered in the study are as follows:
Novartis International AG (Switzerland) , Vertex Pharmaceuticals Incorporated (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation